COMMUNIQUÉS West-GlobeNewswire

Akers Biosciences Signs US Distribution Agreement with Diagnostica Stago

26/03/2018 - 13:00

THOROFARE, N.J., March 26, 2018 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, has entered into a three- [...]

Apricus Biosciences Announces Scheduling of Vitaros™ End-of-Review Meeting with FDA

26/03/2018 - 13:00

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq: APRI ), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that its end-of-review [...]

Axsome Therapeutics to Present at H.C. Wainwright Annual Global Life Sciences Conference

26/03/2018 - 13:00

NEW YORK, March 26, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM ), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders [...]

Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model

26/03/2018 - 13:00

DEVON, Pa., March 26, 2018 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE ), a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative [...]

Lexicon Pharmaceuticals Announces Regulatory Submissions for Sotagliflozin to Treat Adults With Type 1 Diabetes

26/03/2018 - 13:00

New Drug Application Submitted to U.S. Food and Drug Administration Marketing Authorization Application Submitted to European Medicines Agency THE WOODLANDS, Texas, March 26, 2018 (GLOBE NEWSWIRE) -- Lexicon [...]

Roger Jeffs, Former Co-CEO of United Therapeutics, Joins Pluristem's Strategic Advisory Board

26/03/2018 - 13:00

HAIFA, Israel, March 26, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI ) (TASE: PSTI ), a leading developer of placenta-based cell therapy products, announced today that Dr. Roger Jeffs has joined [...]

Loxo Oncology Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Larotrectinib for the Treatment of TRK Fusion Cancer

26/03/2018 - 12:45

STAMFORD, Conn., March 26, 2018 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq: LOXO ), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers [...]

Avivagen Announces Continued Growth and Adoption in the Commercial Use of OxC-beta™ Livestock in the Philippines

26/03/2018 - 12:30

OTTAWA, March 26, 2018 (GLOBE NEWSWIRE) -- Avivagen Inc. (TSXV:VIV) (OTC Pink:CHEXF) (“Avivagen” or the “Corporation”), a life sciences corporation focused on developing and commercializing products for livestock, [...]

Fennec Provides Business Update and Announces Fiscal Year Ended December 31, 2017 Financial Results

26/03/2018 - 12:30

Phase 3 SIOPEL 6 study met primary endpoint (p=0.0033) NASDAQ listing in September 2017 Two equity financings completed Strong financial position at year end with $28.3 million in cash and no debt RESEARCH TRIANGLE PARK [...]

Peeps Marshmallow Candies May be Among Worst Dental Offenders Says Doug Disraeli D.D.S.

26/03/2018 - 12:00

SAN DIEGO, March 26, 2018 (GLOBE NEWSWIRE) -- While peeps may be delicious in springtime, Dr. Doug Disraeli warns that the marshmallow bunnies and chicks are at the top of his list of candies to avoid. Says Dr. Disraeli [...]

Amphastar Pharmaceuticals to Present at the Needham’s 17th Annual Healthcare Conference

26/03/2018 - 12:00

RANCHO CUCAMONGA, Calif., March 26, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) announced today that Bill Peters, CFO will be presenting at the Needham‘s 17 th Annual Healthcare Conference [...]

Helsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards

26/03/2018 - 09:00

H elsinn Advanced Synthesis wins across all categories at the 2018 CMO Leadership Awards For the fourth year running, Helsinn Advanced Synthesis has won first place in all core award categories at the 2018 CMO [...]

Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018

26/03/2018 - 08:09

Curetis To Attend Key Investor and Scientific Conferences In The Second Quarter 2018 Amsterdam, the Netherlands, San Diego, CA, USA and Holzgerlingen, Germany, March 26, 2018, 02:00 a.m. EST -- Curetis N.V. (the " [...]

Notice of Annual General Meeting in Immunicum AB (publ)

26/03/2018 - 08:01

Press Release 26 March 2018 Notice of Annual General Meeting in Immunicum AB (publ) The shareholders of Immunicum AB (publ) (the "Company"), reg. no 556629-1786, are hereby invited to the Annual General Meeting on [...]

Shire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder Treatment

26/03/2018 - 08:00

Shire and NanoMedSyn Enter Into Research Agreement for Potential Lysosomal Storage Disorder Treatment Research agreement focuses on evaluating a potential treatment for a lysosomal storage disorder using NanoMedSyn's [...]

Verona Pharma Reports Positive Top-Line Data from Phase 2b Clinical Trial of RPL554 for Maintenance Treatment of COPD

26/03/2018 - 08:00

Primary endpoint met; RPL554 produced clinically and statistically significant improvements in lung function at all dose levels Clinically relevant secondary endpoints were also met, including statistically significant [...]

PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

26/03/2018 - 07:11

REGULATED INFORMATION GHENT, Belgium, 26 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major [...]

ABLYNX ANNOUNCES TOPLINE RESULTS FROM THE PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

26/03/2018 - 07:01

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 26 March 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that the Phase II dose-ranging study of vobarilizumab, the Company's anti-IL-6R [...]

argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe

26/03/2018 - 07:01

March 26, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the [...]